NR3C2 and chronic kidney disease: Balcinrenone, a selective MR modulator, was studied alongside dapagliflozin to assess their combined effects on UACR changes compared with dapagliflozin alone over 12 weeks in patients with symptomatic HF and LVEF <60% and CKD.